foxo1a Antibody

What is FOXO1A and why is it important in research?

FOXO1 (also known as FOXO1A or FKHR) is a transcription factor belonging to the O subfamily of forkhead box-containing proteins. With a molecular weight of approximately 69-70 kDa and 655 amino acid residues, FOXO1 is ubiquitously expressed and localizes to both the nucleus and cytoplasm .

FOXO1 is significant in research because it:

• Functions as a main target of insulin signaling and regulates metabolic homeostasis

• Mediates responses to oxidative stress

• Regulates genes involved in cell metabolism, growth, and differentiation

• Plays crucial roles in B cell maturation and class-switch recombination

• Participates in regulatory T cell function

• Is implicated in various diseases, including cancer (particularly rhabdomyosarcoma)

The fact that FOXO1-deficient mice are embryonically lethal underscores its essential functions in development that cannot be compensated by other FoxO family members .

What applications are FOXO1A antibodies suitable for?

FOXO1A antibodies can be used in multiple research applications:

Different antibody clones demonstrate varying levels of reactivity with human, mouse, and rat samples. For instance, clone W20064D has verified reactivity with both human and mouse samples, while some clones are specific only to human FOXO1A .

How should I validate the specificity of a FOXO1A antibody?

Proper validation of FOXO1A antibodies is crucial for experimental reliability:

• Knockout/knockdown validation: Use FOXO1 knockout or knockdown cells as negative controls. For example, one antibody (ab179450) was validated using FOXO1 knockout HAP1 cells, showing specific reaction with FOXO1 in wild-type cells but no bands in knockout samples .

• Known positive and negative cell lines: Some antibodies have been tested in cell lines with known FOXO1 expression profiles. For instance, Daudi (Burkitt's lymphoma) cells show positive staining while MOLT-4 (acute lymphoblastic leukemia) cells are negative .

• Western blot analysis: Verify the molecular weight matches the expected ~69-70 kDa. Be aware that FOXO1 may appear as a 70-75 kDa band due to post-translational modifications .

• Competing peptides: Use blocking peptides corresponding to the immunogen to confirm specificity.

• Multiple application testing: Confirm consistent results across different techniques (WB, IHC, ICC) for increased confidence in specificity.

What are appropriate controls for FOXO1A antibody experiments?

When working with FOXO1A antibodies, implement these controls:

• Positive controls: Use cell lines with known FOXO1 expression such as:

  • HepG2, HeLa, and 293T cell lines for Western blot

  • LNCaP prostate cancer cell line for immunocytochemistry

  • Daudi cells for flow cytometry

  • Human tonsil tissue for IHC

• Negative controls:

  • FOXO1 knockout cell lines created using CRISPR/Cas9

  • MOLT-4 cells for certain antibody clones

  • Primary antibody omission (substitute with buffer or isotype control)

  • Irrelevant tissues known to lack FOXO1 expression

• Loading controls: Use GAPDH, β-actin, or β-tubulin for Western blots .

How can I detect FOXO1A post-translational modifications?

FOXO1 undergoes several post-translational modifications that affect its function and localization:

Phosphorylation detection:

• Use phospho-specific antibodies targeting known sites (e.g., Ser256)

• Combine with phosphatase inhibitors in lysis buffers

• Consider lambda phosphatase treatment as a negative control

• Use insulin treatment (increases FOXO1 phosphorylation via AKT) as a positive control

Methylation detection:

• FOXO1 is methylated by G9a at K273 residue, which affects its stability

• Use methyl-lysine antibodies (such as ab-7375) for immunoprecipitation followed by FOXO1 detection

• Treat cells with G9a inhibitor BIX-01294 as a negative control

Ubiquitination detection:

• Treat cells with proteasome inhibitor MG132 (20 μM, 6h before lysis)

• Use modified RIPA buffer (10 mM Tris–HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 0.025% SDS, protease inhibitors)

• Immunoprecipitate with anti-ubiquitin antibody and immunoblot with anti-FOXO1

Acetylation detection:

• Immunoprecipitate FOXO1 and immunoblot with anti-acetyl-lysine antibodies

• HDAC inhibitor treatment can be used as a positive control

How can I study FOXO1A subcellular localization?

FOXO1 shuttles between the nucleus and cytoplasm based on its phosphorylation status. To study this:

• Cell fractionation approach:

  • Separate nuclear and cytoplasmic fractions using appropriate fractionation protocols

  • Analyze FOXO1 distribution by Western blot

  • Verify fraction purity using nuclear markers (H3, Lamin B) and cytoplasmic markers (GAPDH, tubulin)

• Immunofluorescence approach:

  • Use FOXO1 antibodies validated for ICC (e.g., 5.0 μg/ml concentration)

  • Counterstain with DAPI to visualize nuclei

  • Insulin or growth factor treatment (30 minutes) typically leads to cytoplasmic translocation

  • Image using confocal microscopy for precise localization

• Stimulation experiments:

  • Insulin treatment promotes FOXO1 translocation from nucleus to cytoplasm via PI3K/AKT pathway

  • Oxidative stress can trigger nuclear accumulation

  • Use inhibitors like PI3K inhibitors or AKT inhibitors to block translocation

How can I use FOXO1A antibodies to study protein-protein interactions?

FOXO1 interacts with numerous proteins that regulate its function:

• Co-immunoprecipitation protocols:

  • Use RIPA buffer (50 mM Tris–HCl [pH 8.0], 150 mM NaCl, 0.1% SDS, 0.5% SDC, 1% NP-40, protease inhibitors, 1 mM EDTA)

  • Immunoprecipitate overnight at 4°C with anti-FOXO1 antibodies

  • Use Protein A/G agarose beads for 2 hours at 4°C

  • Analyze interacting proteins by immunoblotting

• Known interaction partners that can be studied:

  • G9a (interacts with FOXO1 Forkhead domain via its ANK domain)

  • SKP2 (E3 ligase that regulates FOXO1 stability)

  • RUNX2, NLK, SIRT1, PRMT1, ATF4, and p300

• Domain mapping:

  • The Forkhead domain of FOXO1 is crucial for many protein-protein interactions

  • Study interaction with deletion constructs of FOXO1 to map interaction domains

What methodologies are optimal for studying FOXO1A in cancer research?

FOXO1A plays significant roles in cancer biology:

• Tissue microarray analysis:

  • Use formalin-fixed, paraffin-embedded tissue arrays containing cancer and normal tissues

  • Deparaffinize in xylene and rehydrate in graded ethanol

  • Block endogenous peroxidase with 3% hydrogen peroxide

  • Perform antigen retrieval in citrate buffer (pH 6.0)

  • Use anti-FOXO1 antibodies (1:100 dilution) followed by appropriate secondary antibodies

  • Develop with DAB and counterstain with eosin

• Cancer cell line experiments:

  • FOXO1 expression can be assessed in colon cancer cell lines such as HCT116, DLD-1, and SW480

  • Compare FOXO1 protein levels between normal and cancer cells

  • Study the effect of FOXO1 knockdown or overexpression on cancer cell proliferation and apoptosis

• CRISPR/Cas9 knockout approach:

  • A guide sequence (5′-GCGCGAGCTCAATGACCGGC-3′) targeting the first exon of FOXO1 can be used

  • Clone the guide sequence into a lentiCRISPRv2 vector

  • Transfect cancer cells and select with puromycin

  • Validate knockout by Western blotting and sequencing

• Apoptosis analysis:

  • Treat cells with FOXO1 modulators (e.g., G9a inhibitor BIX-01294)

  • Analyze apoptosis by Annexin V-FITC and propidium iodide staining

  • Perform flow cytometry using appropriate instruments (e.g., BD Accuri C6 Plus)

How do FOXO1A antibodies perform in knockout/knockdown validation experiments?

Rigorous validation using gene silencing approaches is critical:

• siRNA knockdown protocol:

  • Transfect cells with chemically synthesized siRNA targeting FOXO1 (e.g., ID# s5259, Ambion)

  • Use transfection reagents like siPORT NeoFX according to manufacturer's instructions

  • Verify knockdown by qRT-PCR at 48-72 hours post-transfection

  • Confirm protein reduction by Western blot

• CRISPR/Cas9 knockout methodology:

  • Target the first exon of FOXO1 using appropriate guide RNA

  • Clone into lentiCRISPRv2 vector and transfect cells

  • Select with puromycin (e.g., 500 ng/ml for 3 days)

  • Isolate single clones

  • Validate knockout by Western blotting and DNA sequencing

• Western blot validation example:

  • Wild-type and FOXO1 knockout samples should be run in parallel

  • Anti-FOXO1 antibody at 1/1000 dilution

  • Include loading control (GAPDH)

  • FOXO1 antibody should show bands only in wild-type samples, not in knockout samples

What are common issues in FOXO1A Western blotting and how can they be resolved?

For optimal Western blot results:

• Use 30-50μg total protein from cell lysates

• For FOXO1 detection, the recommended antibody concentration is 0.5-2.0 μg/ml

• Block with 5% non-fat milk/TBS for 1.5 hours at room temperature

• Incubate with primary antibody overnight at 4°C

• Wash with TBS-0.1% Tween 3 times for 5 minutes each

• Expect a band at approximately 70 kDa

How can I optimize FOXO1A immunoprecipitation experiments?

For successful FOXO1A immunoprecipitation:

• Optimized lysis conditions:

  • Use RIPA buffer (50 mM Tris–HCl [pH 7.5-8.0], 150 mM NaCl, 0.1% SDS, 0.5% SDC, 1% NP-40, protease inhibitors, 1 mM EDTA)

  • Include phosphatase inhibitors if studying phosphorylation

• IP protocol optimization:

  • Use 250-500μg of protein from whole cell lysates

  • Immunoprecipitate overnight at 4°C with 5-20 μg/ml of anti-FOXO1 antibody

  • Add Protein A/G agarose beads for 2 hours with gentle agitation at 4°C

  • Wash extensively to reduce background

• Controls to include:

  • IgG control (same species as primary antibody)

  • Input control (5-10% of lysate used for IP)

  • Knockout/knockdown cell lysate as negative control